Last $69.03 USD
Change Today +0.12 / 0.17%
Volume 566.0K
CBST On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
NASDAQ GS
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael W. Bonney B.A.

Chief Executive Officer and Director, Cubist Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 27 board members in 4 different organizations across 6 different industries.

See Board Relationships
56$6,606,945
As of Fiscal Year 2013

Background*

Mr. Michael W. Bonney, also known as Mike, B.A. has been the Chief Executive Officer of Cubist Pharmaceuticals Inc. of Calixa Therapeutics, Inc. since June 11, 2003. Mr. Bonney served as President of Cubist Pharmaceuticals Inc. from January 2002 to July 2, 2012. He was employee at Biogen Idec Ma Inc. He served as Chief Executive Officer and President of TerraGen Discovery, Inc. since June 11, 2003. He oversaw the most successful launch of an I.V. antibiotic (Cubicin(R)) ...

Read Full Background

Corporate Headquarters*

65 Hayden Avenue
Lexington, Massachusetts 02421

United States

Phone: 781-860-8660
Fax: --

Board Members Memberships*

2003-Present
Chief Executive Officer and Director
2003-N/A
Former Chief Executive Officer, President and Director
2005-Present
Director and Chairman of Nominating & Corporate Governance Committee
2011-Present
Trustee, Chairman of Governance & Nominating Committee and Member of Valuation Committee
2011-Present
Independent Trustee, Chairman of Governance & Nominating Committee and Member of Valuation Committee

Education*

BA
Bates College

Other Affiliations*

Annual Compensation*

Salary$750,000
Total Annual Compensation$750,000

Stock Options*

Restricted Stock Awards$2,499,994
All Other Compensation$16,953
Exercised Options165,452
Exercised Options Value$5,903,821
Exercisable Options1,054,508
Exercisable Options Value$49,584,983
Unexercisable Options344,536
Unexercisable Options Value$10,124,797
Total Value of Options$65,613,600
Total Number of Options1,564,496

Total Compensation*

Total Annual Cash Compensation$1,606,953
Total Short Term Compensation$750,000
Other Long Term Compensation$2,516,947
Total Calculated Compensation$6,606,945
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $69.03 USD +0.12

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Senior Vice President of Finance, Treasurer and Director
Theravance Inc.
$515.4K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Carolyn J. Logan Chief Executive Officer, President and Director
Salix Pharmaceuticals Ltd.
$867.5K
Eduardo Javier Sanchiz Yrazu Chief Executive Officer, Member of Management Board, Chief Executive of Corporate Development & Finance, Executive Director and Member of Compliance Committee
Almirall, S.A.
--
Richard Martin Steeves BSc., Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.